Ocrelizumab: A Review in Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2018 at "CNS Drugs"
DOI: 10.1007/s40263-018-0568-7
Abstract: Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). In the two identically designed, 96-week OPERA I and II… read more here.
Keywords: sclerosis; review multiple; treatment; multiple sclerosis ... See more keywords